Who can use Krazati(Adagrasib)?

KRAZATI is indicated for the treatment of adult patients with locally advanced or metastatic non - small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one prior systemic therapy, as determined by an FDA - approved test.

Who can use Krazati(Adagrasib)?

This indication was granted accelerated approval based on the objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon the verification and description of clinical benefit in confirmatory trials.

Adagrasib is an oral small - molecule drug that belongs to the class of irreversible inhibitors of the RAS GTPase family, specifically targeting the KRAS G12C mutant protein. It covalently binds to the cysteine residue of this mutant protein, thereby inhibiting the activity of the KRAS protein, locking it in an inactive state, and further blocking downstream signaling pathways, inhibiting the proliferation of tumor cells and inducing their apoptosis.